Page 54 - IMO-2-2

Innovative Medicines & Omics Alzheimer’s disease and clinical trials

lowers amyloid-beta peptide levels in cell culture and mice. PF-06648671, on CSF Amyloid-β peptides in randomized
J Pharmacol Exp Ther. 2007;320:386-396. phase I studies. Clin Pharmacol Ther. 2020;107:211-220.
doi: 10.1124/jpet.106.112102 doi: 10.1002/cpt.1570
103. Vossel K, Ranasinghe KG, Beagle AJ, et al. Effect of 113. Imbimbo BP, Frigerio E, Breda M, et al. Pharmacokinetics
levetiracetam on cognition in patients with Alzheimer and pharmacodynamics of CHF5074 after short-term
disease with and without epileptiform activity: A randomized administration in healthy subjects. Alzheimer Dis Assoc
clinical trial. JAMA Neurol. 2021;78:1345-1354. Disord. 2013;27:278-286.
doi: 10.1001/jamaneurol.2021.3310 doi: 10.1097/WAD.0b013e3182622ace
104. Cumbo E, Ligori LD. Levetiracetam, lamotrigine, and 114. Villemagne VL, Rowe CC, Barnham KJ, et al. A randomized,
phenobarbital in patients with epileptic seizures and exploratory molecular imaging study targeting amyloid β
Alzheimer’s disease. Epilepsy Behav. 2010;17:461-466. with a novel 8-OH quinoline in Alzheimer’s disease: The
PBT2-204 IMAGINE study. Alzheimers Dement (N Y).
doi: 10.1016/j.yebeh.2010.01.015
2017;3:622-635.
105. Reger MA, Watson GS, Green PS, et al. Intranasal insulin
improves cognition and modulates beta-amyloid in early doi: 10.1016/j.trci.2017.10.001
AD. Neurology. 2008;70:440-448. 115. Kutzsche J, Jurgens D, Willuweit A, et al. Safety and
pharmacokinetics of the orally available antiprionic
doi: 10.1212/01.WNL.0000265401.62434.36
compound PRI-002: A single and multiple ascending dose
106. Craft S, Baker LD, Montine TJ, et al. Intranasal insulin phase I study. Alzheimers Dement (N Y). 2020;6:e12001.
therapy for Alzheimer disease and amnestic mild cognitive
impairment: A pilot clinical trial. Arch Neurol. 2012;69:29-38. doi: 10.1002/trc2.12001
doi: 10.1001/archneurol.2011.233 116. Holthoewer D, Endres K, Schuck F, Hiemke C, Schmitt U,
Fahrenholz F. Acitretin, an enhancer of alpha-secretase
107. Chapman CD, Schioth HB, Grillo CA, Benedict C. expression, crosses the blood-brain barrier and is
Intranasal insulin in Alzheimer’s disease: Food for thought. not eliminated by P-glycoprotein. Neurodegener Dis.
Neuropharmacology. 2018;136:196-201. 2012;10:224-228.
doi: 10.1016/j.neuropharm.2017.11.037 doi: 10.1159/000334300
108. Wang HY, Lee KC, Pei Z, Khan A, Bakshi K, Burns LH. PTI- 117. Endres K, Fahrenholz F, Lotz J, et al. Increased CSF APPs-α
125 binds and reverses an altered conformation of filamin levels in patients with Alzheimer disease treated with
A to reduce Alzheimer’s disease pathogenesis. Neurobiol acitretin. Neurology. 2014;83:1930-1935.
Aging. 2017;55:99-114.
doi: 10.1212/WNL.0000000000001017
doi: 10.1016/j.neurobiolaging.2017.03.016
118. O’Hare E, Jeggo R, Kim EM, et al. Lack of support
109. Wang HY, Pei Z, Lee KC, et al. PTI-125 reduces biomarkers for bexarotene as a treatment for Alzheimer’s disease.
of Alzheimer’s disease in patients. J Prev Alzheimers Dis. Neuropharmacology. 2016;100:124-130.
2020;7:256-264.
doi: 10.1016/j.neuropharm.2015.04.020
doi: 10.14283/jpad.2020.6
119. LaClair KD, Manaye KF, Lee DL, et al. Treatment with
110. Hoffmann T, Rahfeld JU, Schenk M, et al. Combination of bexarotene, a compound that increases apolipoprotein-E,
the glutaminyl cyclase inhibitor PQ912 (Varoglutamstat) provides no cognitive benefit in mutant APP/PS1 mice. Mol
and the murine monoclonal antibody PBD-C06 (m6) shows Neurodegener. 2013;8:18.
additive effects on brain Aβ pathology in transgenic Mice.
Int J Mol Sci. 2021;22:11791. doi: 10.1186/1750-1326-8-18
120. Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H,
doi: 10.3390/ijms222111791
Weller RO. Neuropathology of human Alzheimer disease
111. Vijverberg EGB, Axelsen TM, Bihlet AR, et al. Rationale after immunization with amyloid-beta peptide: A case
and study design of a randomized, placebo-controlled, report. Nat Med. 2003;9:448-452.
double-blind phase 2b trial to evaluate efficacy, safety,
and tolerability of an oral glutaminyl cyclase inhibitor doi: 10.1038/nm840
varoglutamstat (PQ912) in study participants with MCI and 121. Maia MA, Sousa E. BACE-1 and γ-secretase as therapeutic
mild AD-VIVIAD. Alzheimers Res Ther. 2021;13:142. targets for Alzheimer’s disease. Pharmaceuticals (Basel).
2019;12:41.
doi: 10.1186/s13195-021-00882-9
doi: 10.3390/ph12010041
112. Ahn JE, Carrieri C, Dela Cruz F, et al. Pharmacokinetic
and pharmacodynamic effects of a γ-secretase modulator, 122. May PC, Willis BA, Lowe SL, et al. The potent

Volume 2 Issue 2 (2025) 48 doi: 10.36922/IMO025050007